We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ongoing Phase I trial shows potential for stand-alone, unboosted agent against COVID-19 Gross proceeds made available to Pardes Biosciences from transaction totaled approximately $274 million...
Proposed merger heads to shareholder vote on December 23rd as ongoing Phase I trial shows potential for unboosted oral regimen In advance of the shareholder vote for the business combination...
FS Development Corp. II, a Delaware corporation (the “Company”) (Nasdaq: FSII), announced today that its registration statement on Form S-4 (File No. 333-258442) (as amended, the “Registration...
CARLSBAD, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating...
CARLSBAD, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., an early-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to...
Leading institutional and strategic investors commit $75 million through a common stock private investment in public equity (“PIPE”) led by Foresite Capital, as well as Gilead Sciences, RA...
FS Development Corp. II (the “Company”) announced today that it priced its initial public offering of 17,500,000 shares of Class A common stock at $10.00 per share. The shares will be listed on...
Tokyo Electron Limited Completes Acquisition of FSI International, Inc. PR Newswire TOKYO, Oct. 11, 2012 TOKYO, Oct. 11, 2012 /PRNewswire/ -- Tokyo Electron Limited ("Tokyo Electron";...
Tokyo Electron Limited Announces Completion of Tender Offer for FSI International, Inc. PR Newswire TOKYO, Oct. 11, 2012 TOKYO, Oct. 11, 2012 /PRNewswire/ -- Tokyo Electron Limited ("Tokyo...
Tokyo Electron Limited Extends Tender Offer to Acquire FSI International, Inc. PR Newswire TOKYO, Sept. 25, 2012 TOKYO, Sept. 25, 2012 /PRNewswire/ -- Tokyo Electron Limited ("Tokyo Electron";...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions